The >>>> Next_Charm$

[bobafett]

$HDVY NEWS pps and volume increasing.....
I have always said one the ceo resigns its time for some action!
http://finance.yahoo.com/news/health-discovery-corporation-issues-corporate-130000321.html
$HDVY No float imo.....

http://charts.insidestocks.com/procal.asp?sym=hdvy
http://www.marketwatch.com/investing/stock/hdvy
http://barchart.com/quotes/stocks/hdvy

First Time Profitability: The Company expects to announce its first profitable quarter in the upcoming Form 10-Q. In addition, the Company has no long-term debt.

NeoGenomics (NGNM),: The Company signed a Worldwide Licensing Agreement with NeoGenomics on January 6, 2012 for Laboratory Developed Test (LDT) rights for hematopoietic and solid tumor cancers. Under the terms of the Agreement, NeoGenomics paid $1 million in cash and issued 1,360,000 (one million three hundred and sixty thousand) shares of NeoGenomics common stock to HDC valued at $1.43 per share (then valued at $1,945,000.00) in upfront licensing fees. Since that time, the NeoGenomics stock price has increased closing at $2.80 per share on Friday, October 22, 2012. On August 13, 2012, HDC sold 409,000 shares of the NeoGenomics stock and received proceeds, net of fees, in the amount of $891,363.00. The Company still retains ownership of 951,000 shares of NeoGenomics stock which is freely tradable and valued at $2,662,800.00 based on the October 22 closing price.

In addition, NeoGenomics will make milestone payments, in cash or stock, based on sublicensing revenue and revenue generated from products and services developed as a result of the Agreement. Milestone payments will be in increments of $500,000 for every $2 million in revenue recognized by NeoGenomics up to a total of $5 million in total milestone payments. After $20 million in cumulative revenue has been recognized, NeoGenomics will pay a royalty of 6.5% on product sales and will share profits from sub-licensing arrangements. In addition, NeoGenomics will pay a royalty of 50% of the revenue recognized from any sub-licensing arrangements for the Cytogenetics Interpretation System and the Flow Cytometry System.
\
Retinalyze, LLC: Retinalyze, LLC is a 50/50 joint venture between Health Discovery Corporation and Doctors Optimal Formula, LLC formed October 18, 2011 to develop SVM based analysis tools for diagnosing diseases such as macular degeneration using fundoscopic images of the eye.

On February 17, 2012, the Company announced the commercial launch of Retinalytics SVMTM, to assist Ophthalmologists and Optometrists in the Detection of Macular Degeneration. While the first Retinalytics SVMTM product released focuses on age-related macular degeneration (“AMD”), the Company continues to develop a second Retinalytics SVMTM product using fundoscopic images of retinal vessels to assist eye care professionals in the detection of Alzheimer’s disease and diabetic retinopathy.

At the end of the 3rd Quarter, 2012 there have been 753 Doctors signed up to use the service and 1700 scans were sent for analysis during the 3rd Quarter for a total of 2,274 scans analyzed to date. Revenue numbers and further detail will be provided in the upcoming 10Q.

SVM Capital: SVM Capital, LLC (“SVM Capital”) is a joint venture between Atlantic Alpha Strategies, LLC (“AA”), a Savannah, Georgia based Registered Investment Advisor (RIA) and Health Discovery Corporation, Inc. (OTCBB: HDVY and “HDC”), a Savannah, Georgia based molecular diagnostics company that uses patent protected SVM technology for personalized medicine. The purpose in forming the joint venture was to apply the advanced mathematical pattern recognition techniques as demonstrated by HDC's SVM technology and intellectual property (“IP”) assets and leverage their capabilities for the first time in the financial markets.

As part of the joint venture agreement, SVM Capital acquired the exclusive and perpetual right to apply HDC’s patent protected SVM technologies to all financial markets world-wide. Since executing their joint venture agreement in 2007, SVM Capital has developed and live traded a series of fully automated trading models based on an initial ETF strategy, the first investment program developed as a result of the joint venture. The results of this ETF program are audited and available for review. A second trading program, using a long/short large cap hedging strategy began live trading in July 2012 and a third and fourth program, currently in development and based on a small cap and mid cap strategy respectively, have yet to begin live trading.

SVM Capital desires to rapidly grow the joint venture and is now evaluating potential joint venture partnerships, IP licensing opportunities and/or various strategic alternatives, including mergers and acquisitions as a means to realize this objective. SVM Capital is actively targeting a combination of individual traders, investment analysts, hedge funds and brokerage firms in addition to research organizations, financial data providers, and financial technology providers as potential clients and/or partners.

Smart Personalized Medicine, LLC: Health Discovery Corporation owns an equity position in and has signed a Licensing Agreement with Smart Personalized Medicine, LLC, founded by Dr. Richard Caruso, Chairman and Founder of Intergra Life Sciences (IART) to work to develop a novel breast cancer prognostic test using HDC’s support vector machine (SVM) technology in collaboration with MD Anderson Cancer Center. Smart Personalized Medicine, LLC and HDC recently terminated their development agreement with Quest Diagnostics and plan to identify a new partner to complete the development of this breast cancer test.

MelApp: MelApp is the world’s first SVM-based iPhone App for assessing the risk of melanoma. MelApp uses highly sophisticated patent protected state-of-the-art mathematical algorithms and image based pattern recognition technology to analyze the uploaded image and give an indication if a mole is low, moderate, or high risk of being a melanoma. In all cases, MelApp refers the App user to a physician for an appropriate medical evaluation. It is an educational tool never to be used as a substitute for a physician diagnosis.

There have been approximately 11,500 MelApp downloads purchased to date. In addition to the revenue generated from the App itself, the Company hopes to generate additional revenue from physician subscriptions for potential patient referrals and advertising for sun care and protection product companies as soon as there is sufficient critical mass in the ordering patterns.

Patent Portfolio: The Company now holds the exclusive rights to 57 issued U.S. and foreign patents covering uses of SVM and FGM technology for discovery of knowledge from large data sets. The Company also has 23 pending U.S. and foreign patent applications covering uses of the SVM technology as well as biomarkers and diagnostic methods that have been discovered using the SVM technology.